Dupixent and T-Cell Lymphoma Lawsuits: What You Need to Know

What Is Dupixent?

Dupixent, known generically as dupilumab, is a prescription medication first approved by the FDA less than a decade ago. It works by blocking certain proteins involved in inflammation, which helps calm the immune response that drives conditions like eczema.

The drug is prescribed for a range of inflammatory conditions, including:

• Eczema and atopic dermatitis. These remain the most common reasons Dupixent is prescribed.
• Asthma. The drug is used to treat certain moderate to severe cases.
• Chronic rhinosinusitis with nasal polyps. Dupixent is approved for this condition as well.
• Other allergic conditions. Additional approved uses have expanded the patient population.

Dupixent has been commercially successful, with sales projected to reach significant figures in 2026. Its widespread use means a large number of patients have been exposed to the drug.

What Is Cutaneous T-Cell Lymphoma?

Cutaneous T-cell lymphoma, often shortened to CTCL, is a rare form of non-Hodgkin lymphoma. It begins in T-cells, which are part of the immune system, and instead of fighting infection these abnormal cells attack the skin.

CTCL often appears as:

• Persistent rashes. Patches of irritated skin that do not heal.
• Scaly or itchy patches. Areas that resemble common skin conditions.
• Skin discoloration. Changes in skin color that do not improve with treatment.

The two most common forms are mycosis fungoides, which often begins as red, scaly patches resembling eczema, and Sézary syndrome, a more aggressive form that causes widespread redness and cancer cells in the blood. 

Because early CTCL can look so much like eczema, it is sometimes mistaken for a common skin condition.

What the Research and Lawsuits Allege

The Dupixent lawsuits center on the allegation that the drug's manufacturers failed to adequately warn patients and doctors about a possible cancer risk. Medical research has given weight to these concerns.

Studies and litigation have focused on several issues, including:

• Elevated risk in research. A matched cohort analysis reported a higher relative risk of CTCL among dupilumab-treated patients compared to non-users.
• Masked symptoms. The drug may suppress visible skin symptoms and hide the early signs of lymphoma.
• Delayed diagnosis. This masking effect may delay an accurate diagnosis for some patients.
• Disease progression. Some patients saw their disease advance while symptoms were suppressed.

Researchers consistently note that these findings show a possible association rather than confirmed causation. No court has found that Dupixent causes cancer, and the manufacturers deny any wrongdoing.

Is the FDA Reviewing Dupixent?

Yes. The U.S. Food and Drug Administration is actively reviewing reports of CTCL in patients who used Dupixent, including reports submitted to its adverse event database.

As of early 2026, the FDA has not added a boxed warning or a specific cancer warning to the Dupixent label. 

The agency is evaluating whether updates to the drug's safety labeling are warranted, and it encourages doctors to closely monitor patients whose skin symptoms are unusual or worsening. The absence of a cancer warning on the current label is one of the central points raised in the litigation.

Where the Litigation Stands

The Dupixent litigation is still in its early stages. In February 2026, attorneys filed a motion with the U.S. Judicial Panel on Multidistrict Litigation asking that federal cases be centralized into a multidistrict litigation, with a hearing on the matter scheduled for May 28, 2026.

At this stage, Dupixent cases are being filed as individual lawsuits rather than as a class action, and there are no jury verdicts or settlements yet. 

Because the litigation is early, much of the current activity involves medical record review and case screening. Patients who believe they may qualify are encouraged not to wait, since legal deadlines apply.